AGOURON NAMES CFO ...Agouron Pharmaceuticals Inc. (NASDAQ:AGPH), a La Jolla,Calif., developer of rational drug treatments for cancer andAIDS, has appointed Steven S. Cowell, former vice presidentand controller of Cetus Corp., to the position of vice presidentand chief financial officer.

Quadra Logic Technologies of Vancouver, British Columbia,appointed John W. Gorder vice president of clinicaldevelopment. Gorder will be responsible for clinical andregulatory affairs and will serve on the executive committee.

Gorder was previously director of medical services in theInternational Marketing Department of Syntex.

Quadra Logic is a pharmaceutical company principally engagedin developing and commercializing drugs that are activated bylight and used for the treatment of disease.

Collagen Corp. of Palo Alto, Calif., said William R. Mullen, vicepresident of operations, and James G. Smith, vice president ofNorth American sales, have resigned to pursue other interests.

MedImmune Inc. (NASDAQ:MEDI) of Gaithersburg, Md., elected Dr.Charles C. Edwards to its board. He is president and chiefexecutive officer of Scripps Clinic and Research Foundation.Edwards, who was FDA commissioner from 1969-73, recentlyserved as chairman of the special advisory committee on theFDA convened by the Department of Health and Human Services.

MedImmune develops, manufactures and marketsimmunotherapeutics and vaccines.

Cephalon Inc., a privately held West Chester, Pa., companytargeting therapeutic products to treat stroke andneurodegenerative disorders, appointed Nicole Vitullo directorof corporate communications. Vitullo had been manager ofhealth care investments for Eastman Kodak Co.

Cellco Inc. a Germantown, Md., manufacturer of products forhuman cellular therapy, appointed Mark E. Keck manager ofsales and marketing. Keck had previously held marketingpositions at Dynatech Laboratories and Life Technologies Inc.

Cytogen Corp (NASDAQ:CYTO) of Princeton, N.J., has promotedCheryl Shipley Coyle to director of marketing. Laura M. Hahnhas has been hired to replace Coyle as director of corporatecommunications. Coyle had worked in the company'scommunications department for the past seven years. Cytogenis focusing on improved cancer diagnostic imaging agents andthe targeted delivery of cancer therapeutic agents directly totumor sites.

Jennifer Van Brunt, Ph.D., Mark J. Friedmann and Deborah J.Lawson have been appointed to the investor relations group ofNoonan/Russo Communications Inc. Van Brunt was previouslymanaging editor of Bio/Technology magazine, Friedmann hadbeen vice president of sales at Startrade Fund, and Lawson wassenior associate of equity research at Kidder, Peabody. NewYork-based Noonan/Russo is a financial public relations firmspecializing in the health care and technology industries.

(c) 1997 American Health Consultants. All rights reserved.